SEC 13F Intelligence

Atlas Venture Associates Ix, LLC / SPRO

Atlas Venture Associates Ix, LLC’s Spero Therapeutics Inc Position

Does Atlas Venture Associates Ix, LLC own Spero Therapeutics Inc (SPRO)? Yes1.35M shares worth $2M (+13.93% of its 13F portfolio) as of Q3 2023.

Position Value
$2M
Q3 2023
Shares
1.35M
% of Portfolio
+13.93%
Quarters Held
20
currently held

Position History SPRO

Reported value by quarter
Q4 ’18: $8MQ4 ’18Q1 ’19: $18MQ2 ’19: $16MQ3 ’19: $15MQ3 ’19Q4 ’19: $13MQ1 ’20: $11MQ2 ’20: $19MQ2 ’20Q3 ’20: $15MQ4 ’20: $27MQ1 ’21: $20MQ1 ’21Q2 ’21: $19MQ3 ’21: $25MQ4 ’21: $22MQ4 ’21Q1 ’22: $12MQ2 ’22: $1MQ3 ’22: $3MQ3 ’22Q4 ’22: $2MQ1 ’23: $2MQ2 ’23: $2MQ2 ’23Q3 ’23: $2Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q3 20231.35M$2M+13.93%
Q2 20231.35M$2M+10.74%
Q1 20231.38M$2M+9.37%
Q4 20221.38M$2M+11.85%
Q3 20221.38M$3M+8.16%
Q2 20221.38M$1M+2.32%
Q1 20221.38M$12M+11.02%
Q4 20211.38M$22M+9.62%
Q3 20211.38M$25M+8.43%
Q2 20211.38M$19M+3.38%
Q1 20211.38M$20M+3.41%
Q4 20201.38M$27M+4.23%
Q3 20201.38M$15M+15.90%
Q2 20201.38M$19M+19.92%
Q1 20201.38M$11M+23.53%
Q4 20191.38M$13M+23.08%
Q3 20191.38M$15M+24.02%
Q2 20191.38M$16M+16.95%
Q1 20191.38M$18M+16.57%
Q4 20181.38M$8M+9.75%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Atlas Venture Associates Ix, LLC’s full portfolio or all institutional holders of SPRO.